학술논문
1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor
Document Type
Abstract
Author
Mezquita, L.; Xenophontos, E.; Pretzenbaher, Y.; Sureda, C.; Nadal, E.; Al-Rabi, K.; Rousseau Bussac, G.; Ponce Aix, S.; Sullivan, I.G.; Calles Blanco, A.; Cloarec, N.; De Langen, J.; Berghmans, T.; Descourt, R.; Hendriks, L.; Garrido Lopez, P.; Helland, A.; Carcereny, E.; Besse, B.; Dingemans, A-M.C.
Source
In Annals of Oncology October 2023 34 Supplement 2:S849-S850
Subject
Language
ISSN
0923-7534